Breaking AI & Tech News Analyzed

Utah has enacted a law that effectively shields fossil fuel companies from legal accountability for climate damages. The legislation, signed by Republican Governor Spencer Cox, limits the ability of residents to sue these companies for their role in contributing to climate change. The new law is part of a broader effort by the fossil fuel industry and its allies to secure legal immunity in statehouses and Congress. This push is aimed at countering a wave of litigation filed by states, subnational governments, and individuals who claim that fossil fuel companies knew their products would cause climate damages but sold them anyway. Critics argue that the law prioritizes profits for the biggest polluters over communities already suffering from climate impacts. The law requires challengers to provide 'clear and convincing evidence' that damage or injury has resulted directly from a violation, making it virtually impossible to successfully sue polluters for climate damages. The legislation was sponsored by Republican Representative Carl Albrecht, who has received funding from oil and gas interests. Albrecht's ties to the industry have raised concerns about the bill's motivations. The law closely mirrors a model policy called the Energy Freedom Act, circulated by the conservative group Consumers Defense, which has financial ties to a group linked to Leonard Leo, a key figure in the far-right takeover of the Supreme Court. The passage of Utah's law comes as climate lawsuits against big oil companies are inching closer to trial. Seventy cities, states, and individuals have sued energy majors for allegedly deceiving the public about the climate crisis. New York and Vermont have also passed climate 'superfund' laws requiring major polluters to pay for damages caused by their past planet-heating pollution. Lawmakers and advocates have amassed evidence that oil companies intentionally covered up the climate harms of their products. Climate science continues to warn that fossil fuels are the primary cause of dangerous global warming. Critics argue that the fossil fuel industry is pushing for immunity because it knows it cannot win on the merits of its case.

Mayor Claudia Kalisch, vice‑president of the German Federation of Cities and leader of the Green‑party city of Lüneburg, announced a push for a nationwide ban on night‑time use of robotic lawnmowers. The proposal aims to curb injuries and deaths among hedgehogs and other small nocturnal animals that frequent residential gardens after dark.Recent research has highlighted that the fast‑moving blades of autonomous mowers pose a hidden danger to wildlife active between dusk and dawn. Hedgehogs, which often curl into a ball when threatened, are especially difficult for mower sensors to detect.Kalisch told the Funke newspaper group that urban green spaces have become critical refuges as development and intensive agriculture shrink natural habitats. She noted that petitions urging the ban have amassed tens of thousands of signatures earlier this year, reflecting broad public concern.In addition to legislative pressure, the mayor called on manufacturers to develop hedgehog‑friendly technology. She emphasized that industry responsibility is essential for protecting biodiversity and improving city life quality.The European red‑list classifies hedgehogs as "near threatened" since 2024, after a documented 30% population decline over the past decade. Beyond mower hazards, motorised leaf blowers, vacuums, and vehicle collisions—responsible for up to one in three fatalities—exacerbate the species’ decline across Europe.Scientists at the University of Oxford, in collaboration with Danish colleagues, recently demonstrated that hedgehogs can hear high‑frequency ultrasound, opening the possibility of sonic road repellers to deter them from dangerous areas. The same team has produced 3D‑printed, crash‑test dummy hedgehogs to work with manufacturers on a future certification scheme for "hedgehog‑safe" mowers.Study co‑author Anne Berger of Germany’s Leibniz Institute for Zoo and Wildlife Research warned that injuries from robotic mowers place an "enormous burden" on animal‑care centres, with many victims discovered days or weeks after the incident, enduring prolonged suffering.German law already protects hedgehogs, imposing fines of up to €65,000 for illegal trapping, injury, or killing. Several cities—including Cologne, Leipzig and Munich—have already outlawed night‑time mower operation. However, a recent attempt by the Greens to enact a statewide ban in Bavaria was rejected.

Reece James is expected to be fit again by the end of April or early May, according to club medical updates, offering a timely lift to England’s 2026 World Cup ambitions. The Chelsea defender has missed action since sustaining a hamstring problem in the defeat to Newcastle last month. Initial assessments warned of a possible two‑month lay‑off, threatening his participation in the summer tournament. England manager Thomas Tuchel now faces a crucial decision on whether to include James in the final 26‑man squad. The right‑back has been Tuchel’s preferred option, having missed recent friendlies against Uruguay and Japan due to injury, while alternatives such as Ben White and Tino Livramento failed to impress. Beyond the national team, Chelsea are eager to see James back. The club sits sixth in the Premier League ahead of a high‑profile clash with Manchester City, and the captain’s recent contract extension to 2032 underscores his importance. James has contributed not only defensively but also with notable performances in central midfield this season. Should James return as projected, his dual‑role versatility could provide Tuchel with a reliable right‑back and give Chelsea a boost in their pursuit of a top‑four finish.

Brighton pulled off a major upset in the Women's FA Cup quarterfinals, defeating Arsenal 2-0 at Borehamwood. The win extended Arsenal's wait for their first Women's FA Cup title in over a decade. Fran Kirby, a former Chelsea forward, played a crucial role in the victory, providing two assists.Madison Haley opened the scoring shortly after halftime with a superb finish into the top corner, and Caitlin Hayes sealed the win with a header from a deep Kirby corner. Arsenal, who had recently knocked out Chelsea in the Champions League, looked disjointed and below their best.In another match, Liverpool secured a semifinal spot with a scrappy 115th-minute goal from substitute Zara Shaw against Charlton Athletic. Shaw's goal came after a scramble in the box, marking her return to competitive action after a 12-month knee injury.Liverpool manager Gareth Taylor praised Shaw's determination, saying, 'What a story, Zara Shaw, eh? The way people speak about her at the club, it couldn’t have happened to a better person.'Charlton's head coach, Karen Hills, expressed pride in her team's performance, stating, 'I’m so proud of the group. The way they performed today, they were outstanding.'

Barcelona will face Atletico Madrid at the Metropolitano Stadium on Saturday, April 5, at 9pm (19:00 GMT), in a critical La Liga encounter. This match serves as a precursor to their Champions League quarterfinal series, with the two Spanish giants set to clash three times in 10 days.The Catalan club will be without winger Raphinha due to a hamstring injury, placing additional pressure on teenage star Lamine Yamal to deliver. The 18-year-old has been in impressive form, scoring six times in his last seven matches across all competitions.Yamal has drawn comparisons to Lionel Messi and has been a key player for Barca, helping the team win Euro 2024 and a domestic treble last season. His maturity and skill on the pitch have been notable, especially in big games.Barcelona currently leads La Liga and will look to maintain or extend their lead against Atletico, who have little to play for in the league but will aim to build momentum for their Champions League quarterfinal against Barca.The match is a rematch of their Copa del Rey semifinal encounter in February and March, where Atletico advanced to the final 4-3 on aggregate. Barcelona is seeking to reach the Champions League semifinals for the second consecutive season, while Atletico aims to return to the last four for the first time since 2017.In terms of team news, Atletico Madrid will be without Marcos Llorente and Johnny Cardoso due to suspensions, as well as Pablo Barrios and Rodrigo Mendoza due to injuries. Barcelona is likely to be without Frenkie de Jong but may see the return of Jules Kounde and Alejandro Balde from injury.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

Real Mallorca delivered a stunning upset to Real Madrid, winning 2‑1 thanks to an added‑time strike from Vedat Muriqi. The victory pushes the champions to four points behind Barcelona ahead of their upcoming clash with Atlético Madrid.The match began with Mallorca absorbing early pressure; goalkeeper Leo Román denied Kylian Mbappé twice with diving saves. Mallorca took the lead in the 42nd minute when Manu Morlanes headed home a cross from Pablo Maffeo.Real responded late, with Éder Militão—returning from a hamstring injury—equalising in the 88th minute. Just three minutes later, Muriqi, the league’s second‑highest scorer behind Mbappé, netted the winner, marking Mallorca’s first triumph over Real in three years and lifting them two points above the relegation zone.Muriqi, who had faced criticism after Kosovo’s World Cup qualifying loss, broke down in tears after the final whistle, saying, "Sometimes emotions get the better of you… I’m just happy to repay the supporters, we want to stay in this division for them."In Germany, Bayern Munich staged a dramatic comeback, scoring three goals in the final nine minutes to edge Freiburg 3‑2. Tom Bischof equalised, and Lennart Karl clinched the winner in stoppage time, despite the absence of injured striker Harry Kane. Bayern now travel to Real Madrid for their Champions League quarter‑final first leg.Freiburg had opened the scoring early in the second half with a long‑range strike from Johan Manzambi, and later doubled the lead via a Lucas Hoeler volley after a corner error by Manuel Neuer. However, Bayern’s late surge erased the deficit.Meanwhile, Borussia Dortmund secured a 2‑0 away win at VfB Stuttgart with late goals from Karim Adeyemi and Julian Brandt. The victory keeps Dortmund in second place on 64 points, nine behind Bayern, while Stuttgart slips to fourth.In Italy, Massimiliano Allegri of AC Milan reiterated his focus on the club, dismissing any immediate interest in the vacant Italy national team manager role after Gennaro Gattuso stepped down following a World Cup playoff defeat.

Even before the season began, the fixture list hinted that March would become a turning point for Newcastle United. A run to the Champions League quarter‑finals and a victory in the Tyne‑Wear derby could have silenced many critics, while a third Carabao Cup final would have forced the derby’s postponement. In the Champions League round‑of‑16, Newcastle appeared stronger at home against Barcelona, only to be undone by a late penalty. The away leg saw them threaten early on, but a second‑half collapse resulted in a 7‑2 defeat, widening the perceived gap between the sides. The derby itself illustrated the team’s frailties. Newcastle led at halftime and struck the post, yet they finished with the fifth‑worst second‑half record in the Premier League. Sunderland equalised through Brian Brobbey, fed by a simple Granit Xhaka pass, exploiting the space that Newcastle’s midfield surrendered late in the game. These setbacks have sparked serious speculation about manager Eddie Howe’s future. Chief executive David Hopkinson offered no clear endorsement, stating only that “we’ll talk about the future when it’s time,” a comment that many interpreted as a warning. Howe arrived in November 2021, a month after the Saudi‑led acquisition of the club, and quickly guided Newcastle into the modern era: two Champions League qualifications, a historic Carabao Cup triumph – the first domestic trophy in 70 years – and a generally steady league performance. Until last season, there was little talk of his dismissal. However, the current crisis is less about tactics than about recruitment. With no sporting director, Howe’s nephew Andy Howe and scout Steve Nickson oversaw most signings last summer, a structure that has drawn criticism. The sale of Alexander Isak to Liverpool was widely regarded as mishandled. The club allowed the protracted saga to dominate the window, missing an opportunity to maximise the fee and reinvest in squad depth, or to negotiate a swap that could have brought Hugo Ekitiké to Newcastle. Summer acquisitions have added little stability. While Sandro Tonali, Anthony Gordon and Tino Livramento are rumored to be on their way out, Yoane Wissa suffered an early injury and new signing Nick Woltemade arrived without a clear role. Of the incoming players, only Malick Thiaw has made a noticeable impact. Consequently, the squad lacks the depth required for simultaneous Champions League commitments, a Carabao Cup semi‑final run, and a fifth‑round FA Cup tie. The fatigue evident in many second‑half performances is therefore unsurprising. Underlying these on‑field issues are broader structural problems. Dan Ashworth’s departure for Manchester United left a void that successor Paul Mitchell could not fill; his exit after clashes with ownership – and reportedly with Howe over player conditioning – created a leadership vacuum. Ross Wilson, appointed sporting director in October with Howe’s blessing, now faces the daunting task of rebuilding a fragmented recruitment process. Financial pressures add another layer of complexity. The recent sale of the stadium to a club subsidiary, coupled with a looming UEFA fine for 2025, has strained resources. While the Champions League revenue and the Isak transfer may alleviate some of the strain, the shift to an “unanchored” squad‑cost ratio favours owners with deep pockets, leaving the club’s commitment from the Public Investment Fund uncertain amid broader Saudi retrenchment. Notably, discussions of a new stadium have been absent for almost a year. Hopkinson’s description of Newcastle as a “trading club” appears realistic, yet his remarks also hint at an upcoming exodus of players such as Tonali, Gordon and Livramento. Even if the broader economic climate softens, the likely absence of Champions League football next season could further limit Newcastle’s ability to attract top talent. Ultimately, the core issue is governance. While Howe’s tactical acumen may improve without the demands of European competition, the club’s ambition to become a modern, well‑structured organisation may require a change in leadership. His departure could be the catalyst needed for a comprehensive cultural and structural overhaul.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.